NEW YORK — Women's health startup Adyn said on Monday that it has raised $2.5 million in seed funding to help advance its birth control selection test.
The round was led by Lux Capital and M13 with participation from Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, and Ascend VC, as well as individual investors Anne Wojcicki of 23andMe, Nish Bhat of Color Genomics, Qasar Younis of Applied Intuition, and Ashley Mayer of Glossier.
Adyn said that the funds will help it commercialize its Birth Control Optimization Test, which uses saliva and finger prick blood samples collected at home to determine a woman's hormone levels and genetic risk of birth control-associated blood clots and depression. These data are integrated with the user's medical history and side effect profiles of estrogens and progestins used in hormonal contraception to make birth control recommendations.
Seattle-based Adyn said it has opened a waitlist for the test, which is expected to ship before the end of the year.